“Duration of Response and Progression-Free Survival with Sonidegib 200 Mg Once Daily Until Disease Progression or Start of New Antineoplastic Therapy in Patients with Locally Advanced Basal Cell Carcinoma: Results of the 42-Month, Randomized, Double-Blind”, J of Skin, vol. 4, no. 5, p. s68, Sep. 2020, doi: 10.25251/skin.4.supp.67.